Information Provided By:
Fly News Breaks for March 28, 2018
AMAG
Mar 28, 2018 | 09:25 EDT
Morgan Stanley analyst Thomas Smith said his initial channel checks point to solid formulary coverage for Amag's Makena subcutaneous auto-injector, which removes one potential barrier to uptake. The analyst, who believes the durability of the Makena franchise depends largely on the company's ability to execute on the auto-injector launch, keeps an Overweight rating on Amag Pharmaceuticals.
News For AMAG From the Last 2 Days
There are no results for your query AMAG